Antibacterial activity of statins: A comparative study of Atorvastatin, Simvastatin, and Rosuvastatin

Annals of Clinical Microbiology and Antimicrobials

Volumn 11, Issue , 2012, Pages

  Masadeh, Majed ^a   Mhaidat, Nizar ^a   Alzoubi, Karem ^a   Al azzam, Sayer ^a   Alnasser, Ziad ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Antimicrobial activity; Atorvastatin; Rosuvastatin; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MIRABILIS; NONHUMAN; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROBENZENES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 84860583669     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-11-13     Document Type: Article

References (36)

1. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010, 33:171-187. 10.2165/11319380-000000000-00000, 20158283.
2. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003, 91:33-41.
3. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008, 13:157-174. 10.1177/1074248408318628, 18460672.
4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565. 10.1001/jama.295.13.jpc60002, 16533939.
5. Furberg CD. Natural statins and stroke risk. Circulation 1999, 99:185-188. 10.1161/01.CIR.99.2.185, 9892578.
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196.
7. Viasus D, Garcia-Vidal C, Gudiol F, Carratala J. Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis 2010, 29:143-152. 10.1007/s10096-009-0835-0, 19943074.
8. Bielinska A, Gluszko P. Statins-are they potentially useful in rheumatology?. Pol Arch Med Wewn 2007, 117:420-425.
9. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005, 25:287-294.
10. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009, 35:1255-1260. 10.1007/s00134-009-1429-0, 19205663.
11. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118. 10.1146/annurev.pharmtox.45.120403.095748, 2694580, 15822172.
12. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007, 7:358-368. 10.1016/S1473-3099(07)70111-1, 17448939.
13. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004, 109:2560-2565. 10.1161/01.CIR.0000129774.09737.5B, 15123521.
14. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005, 112:117-124. 10.1161/CIRCULATIONAHA.104.502195, 15998696.
15. Chaudhry MZ, Wang JH, Blankson S, Redmond HP. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) 2008, 9:183-194.
16. Souza Neto JL, Araujo Filho I, Rego AC, Dominici VA, Azevedo IM, Egito ES, Brandao-Neto J, Medeiros AC. Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras 2006, 21(Suppl 4):8-12.
17. Chen CH, Lee RP, Wu WT, Liao KW, Hsu N, Hsu BG. Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation 2007, 74:166-174. 10.1016/j.resuscitation.2006.12.002, 17353078.
18. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006, 367:413-418. 10.1016/S0140-6736(06)68041-0, 16458766.
19. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004, 110:880-885. 10.1161/01.CIR.0000138932.17956.F1, 15289367.
20. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001, 33:1352-1357. 10.1086/323334, 11565076.
21. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006, 34:1080-1086. 10.1097/01.CCM.0000207345.92928.E4, 16484926.
22. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006, 32:75-79. 10.1007/s00134-005-2859-y, 16283159.
23. Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 2009, 48:745-755. 10.1086/597039, 19193110.
24. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667. 10.1001/archinternmed.2009.286, 19822822.
25. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. M100-S20 2010, Villanova, PA, Available from: [http://www.clsi.org/source/orders/free/m100- s20.pdf www.clsi.org/source/orders/free/m100-s20.pdf]. Accessed 14 September 2011. 2010, Clinical and Laboratory Standards Institute (CLSI).
26. CLSI Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard 2009, Villanova, PA, Eighth, Available from [http://www.clsi.org/source/orders/free/m07-a8.pdf]. Accessed 14 September 2011. 2009, CLSI.
27. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008, 61:362-364.
28. Welsh AM, Kruger P, Faoagali J. Antimicrobial action of atorvastatin and rosuvastatin. Pathology 2009, 41:689-691. 10.3109/00313020903305860, 20001351.
29. Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-Normark B, Andersson J, Bjorkhem-Bergman L. Studies on the antibacterial effects of statins-in vitro and in vivo. PLoS One 2011, 6:e24394. 10.1371/journal.pone.0024394, 3166163, 21912631.
30. Bjorkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. Br J Clin Pharmacol 2011, 72:164-165. 10.1111/j.1365-2125.2011.03907.x, 3141200, 21223360.
31. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, Sawanobori K, Kitahara M, Kodama T, Saito Y. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. J Atheroscler Thromb 2006, 13:295-307. 10.5551/jat.13.295, 17192694.
32. Muck AO, Seeger H, Wallwiener D. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol 2004, 93:398-402. 10.1007/s00392-004-0081-5, 15160275.
33. Tapia-Perez JH, Kirches E, Mawrin C, Firsching R, Schneider T. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 2011, 67:1193-1201. 10.1007/s00280-010-1535-2, 21120479.
34. Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004, 5:248. 10.1186/gb-2004-5-11-248, 545772, 15535874.
35. Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95-101. 10.1097/00005344-199907000-00016, 10413074.
36. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, Shimano H. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006, 13:329-335. 10.5551/jat.13.329, 17192698.